SLT Holdings LLC Purchases Shares of 8,125 Hims & Hers Health, Inc. $HIMS

Key Points

• SLT Holdings LLC has acquired a new stake of 8,125 shares in Hims & Hers Health, Inc. during the second quarter, valued at approximately $405,000.
• Hims & Hers reported a Q2 EPS of $0.17, missing expectations by $0.01, with revenue reaching $544.83 million, up 72.6% from last year.
• Recent analyst reports show a mixed sentiment, with two buy ratings, nine hold ratings, and three sell ratings, reflecting a consensus rating of "Reduce" and a price target of $38.92.

SLT Holdings LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 8,125 shares of the company's stock, valued at approximately $405,000.

A number of other institutional investors have also recently made changes to their positions in HIMS. Nuveen LLC bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at about $58,403,000. Yong Rong HK Asset Management Ltd lifted its stake in shares of Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock valued at $70,920,000 after purchasing an additional 700,100 shares during the period. CloudAlpha Capital Management Limited Hong Kong acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at about $20,580,000. Jump Financial LLC lifted its stake in shares of Hims & Hers Health by 633.2% in the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company's stock valued at $21,437,000 after purchasing an additional 626,496 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company's stock valued at $71,969,000 after purchasing an additional 397,310 shares during the period. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $53.98 on Friday. The company has a market cap of $12.20 billion, a PE ratio of 67.48, a price-to-earnings-growth ratio of 3.93 and a beta of 2.25. Hims & Hers Health, Inc. has a 52 week low of $17.36 and a 52 week high of $72.98. The business has a 50 day moving average price of $50.86 and a 200-day moving average price of $47.90. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analysts' expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period last year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Truist Financial dropped their price objective on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating on the stock in a research note on Monday, August 18th. Weiss Ratings reissued a "hold (c)" rating on shares of Hims & Hers Health in a research note on Saturday, September 27th. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Finally, UBS Group set a $30.00 price target on Hims & Hers Health in a research note on Monday, June 23rd. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 11,595 shares of the stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $57.72, for a total transaction of $669,263.40. Following the completion of the sale, the chief financial officer directly owned 70,232 shares of the company's stock, valued at approximately $4,053,791.04. This trade represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares of the company's stock, valued at $8,581,970. The trade was a 5.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,622,741 shares of company stock valued at $83,695,469. Corporate insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.